Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Feb-24 4:04 PM View:  | Podlesak Dennis Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 34,000 | -- | -- | 32% 107.76K to 141.76K | |
| 09-Feb-24 4:04 PM View: | Jarrett Jennifer Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 35% 48.0K to 65.0K | |
| 09-Feb-24 4:04 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 35% 48.0K to 65.0K | |
| 09-Feb-24 4:04 PM View: | Katkin Keith Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 35% 48.0K to 65.0K | |
| 09-Feb-24 4:04 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 95% 17.84K to 34.84K | |
| 09-Feb-24 4:04 PM View: | Huber Martin H. Jr. Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 53% 32.0K to 49.0K | |
| 09-Feb-24 4:05 PM View: | Metzger Michael A Chief Executive Officer Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 146,250 | -- | -- | 828% 17.66K to 163.91K | |
| 09-Feb-24 4:05 PM View: | Goldan Keith A. Chief Financial Officer | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 46,700 | -- | -- | 999% 4.67K to 51.37K | |
| 09-Feb-24 4:05 PM View: | Gallagher Neil President, Head of R&D | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 47,813 | -- | -- | 100% 0 to 47.81K | |
| 09-Feb-24 4:04 PM View: | Meury William Director | Syndax Pharmaceuticals Inc (SNDX) | 07-Feb-24 | Grant | 17,000 | -- | -- | 35% 48.0K to 65.0K | |
| 09-Feb-24 4:05 PM View: | Goldan Keith A. Chief Financial Officer | Syndax Pharmaceuticals Inc (SNDX) | 31-Jan-24 | Acquisition (other) | 1,183 | $17.42 | $20,607.90 | 34% 3.49K to 4.67K | |
| 10-Aug-23 6:50 AM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-Aug-23 | Option Sale | 52,855 | $18.27 | $965,402.00 | (75%) 70.69K to 17.84K | |
| 10-Aug-23 6:50 AM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-Aug-23 | Option Exercise | 52,855 | $8.77 | $463,538.00 | 296% 17.84K to 70.69K | |
| 03-Aug-23 9:12 AM View: | Meury William Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Aug-23 | Option Exercise | 83,000 | $8.02 | $665,250.00 | 173% 48.0K to 131.0K | |
| 03-Aug-23 9:12 AM View: | Meury William Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Aug-23 | Option Sale | 83,000 | $20.46 | $1,697,810.00 | (63%) 131.0K to 48.0K | |
| 09-Feb-24 4:05 PM View: | Goldan Keith A. Chief Financial Officer | Syndax Pharmaceuticals Inc (SNDX) | 31-Jul-23 | Acquisition (other) | 862 | $18.12 | $15,619.40 | 33% 2.63K to 3.49K | 7% |
| 11-Jul-23 9:23 AM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 10-Jul-23 | Option Exercise | 52,855 | $8.77 | $463,538.00 | 296% 17.84K to 70.69K | |
| 11-Jul-23 9:23 AM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 10-Jul-23 | Option Sale | 52,855 | $20.40 | $1,078,070.00 | (75%) 70.69K to 17.84K | |
| 14-Jun-23 4:20 PM View: | Goldan Keith A. Chief Financial Officer | Syndax Pharmaceuticals Inc (SNDX) | 13-Jun-23 | Private Sale | 577 | $22.31 | $12,872.90 | (18%) 3.21K to 2.63K | |
| 09-Jun-23 5:32 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-Jun-23 | Option Exercise | 52,855 | $7.66 | $404,787.00 | 296% 17.84K to 70.69K | |
| 09-Jun-23 5:32 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-Jun-23 | Option Sale | 52,855 | $21.18 | $1,119,420.00 | (75%) 70.69K to 17.84K | |
| 10-May-23 4:11 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-May-23 | Option Sale | 52,855 | $21.41 | $1,131,480.00 | (75%) 70.69K to 17.84K | |
| 10-May-23 4:11 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 09-May-23 | Option Exercise | 52,855 | $6.38 | $337,215.00 | 296% 17.84K to 70.69K | |
| 12-Apr-23 4:03 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 10-Apr-23 | Option Exercise | 52,855 | $6.38 | $337,215.00 | 296% 17.84K to 70.69K | |
| 12-Apr-23 4:03 PM View: | Morrison Briggs Director | Syndax Pharmaceuticals Inc (SNDX) | 10-Apr-23 | Option Sale | 52,855 | $19.53 | $1,032,240.00 | (75%) 70.69K to 17.84K | |
| 14-Mar-23 4:42 PM View: | Morrison Briggs President, Head of R&D Director | Syndax Pharmaceuticals Inc (SNDX) | 13-Mar-23 | Option Exercise | 52,854 | $6.38 | $337,209.00 | 296% 17.84K to 70.69K | |
| 14-Mar-23 4:42 PM View: | Morrison Briggs President, Head of R&D Director | Syndax Pharmaceuticals Inc (SNDX) | 13-Mar-23 | Planned Option Sale | 52,854 | $22.53 | $1,190,670.00 | (75%) 70.69K to 17.84K | |
| 17-Feb-23 6:09 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 15-Feb-23 | Planned Option Sale | 25,000 | $25.84 | $646,092.00 | (100%) 25.0K to 0 | |
| 17-Feb-23 6:09 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 15-Feb-23 | Option Exercise | 25,000 | $6.95 | $173,791.00 | 100% 0 to 25.0K | |
| 08-Feb-23 4:49 PM View: | Metzger Michael A Chief Executive Officer Director | Syndax Pharmaceuticals Inc (SNDX) | 06-Feb-23 | Planned Option Sale | 5,959 | $27.64 | $164,697.00 | (25%) 23.62K to 17.66K | |
| 08-Feb-23 4:49 PM View: | Morrison Briggs President, Head of R&D Director | Syndax Pharmaceuticals Inc (SNDX) | 06-Feb-23 | Planned Option Sale | 52,854 | $26.83 | $1,417,910.00 | (75%) 70.69K to 17.84K | |
| 08-Feb-23 4:49 PM View: | Metzger Michael A Chief Executive Officer Director | Syndax Pharmaceuticals Inc (SNDX) | 06-Feb-23 | Option Exercise | 5,959 | $6.38 | $38,018.40 | 34% 17.66K to 23.62K | |
| 08-Feb-23 4:49 PM View: | Morrison Briggs President, Head of R&D Director | Syndax Pharmaceuticals Inc (SNDX) | 06-Feb-23 | Option Exercise | 52,854 | $6.38 | $337,209.00 | 296% 17.84K to 70.69K | |
| 03-Feb-23 4:52 PM View: | Jarrett Jennifer Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 16,000 | -- | -- | 50% 32.0K to 48.0K | |
| 03-Feb-23 4:54 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 16,000 | -- | -- | 50% 32.0K to 48.0K | |
| 03-Feb-23 4:57 PM View: | Podlesak Dennis Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 32,000 | -- | -- | 42% 75.76K to 107.76K | |
| 03-Feb-23 4:56 PM View: | Huber Martin H. Jr. Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 16,000 | -- | -- | 100% 16.0K to 32.0K | |
| 03-Feb-23 4:52 PM View: | Katkin Keith Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 16,000 | -- | -- | 50% 32.0K to 48.0K | |
| 03-Feb-23 4:55 PM View: | Meury William Director | Syndax Pharmaceuticals Inc (SNDX) | 02-Feb-23 | Grant | 16,000 | -- | -- | 50% 32.0K to 48.0K | |
| 03-Feb-23 4:59 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 01-Feb-23 | Sale | 69 | $28.43 | $1,961.54 | (100%) 69 to 0 | |
| 03-Feb-23 4:59 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 31-Jan-23 | Acquisition (other) | 69 | $17.32 | $1,195.08 | 100% 0 to 69 | |
| 13-Jan-23 4:44 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 13-Jan-23 | Option Exercise | 15,000 | $13.58 | $203,700.00 | 47% 32.0K to 47.0K | |
| 13-Jan-23 4:44 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 13-Jan-23 | Planned Option Sale | 15,000 | $27.00 | $405,000.00 | (32%) 47.0K to 32.0K | |
| 13-Jan-23 4:44 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 12-Jan-23 | Option Exercise | 24,000 | $9.47 | $227,280.00 | 75% 32.0K to 56.0K | |
| 13-Jan-23 4:44 PM View: | Legault Pierre Director | Syndax Pharmaceuticals Inc (SNDX) | 12-Jan-23 | Planned Option Sale | 24,000 | $26.74 | $641,782.00 | (43%) 56.0K to 32.0K | |
| 02-Dec-22 5:01 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 02-Dec-22 | Option Exercise | 17,200 | $6.38 | $109,736.00 | 6491% 0.27K to 17.46K | |
| 02-Dec-22 5:01 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 02-Dec-22 | Planned Option Sale | 17,200 | $25.05 | $430,936.00 | (98%) 17.46K to 0.27K | |
| 02-Dec-22 5:01 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 01-Dec-22 | Option Exercise | 7,800 | $6.37 | $49,650.80 | 2943% 0.27K to 8.06K | |
| 02-Dec-22 5:01 PM View: | Ordentlich Peter Chief Scientific Officer | Syndax Pharmaceuticals Inc (SNDX) | 01-Dec-22 | Planned Option Sale | 7,800 | $25.01 | $195,089.00 | (97%) 8.06K to 0.27K | |
| 07-Oct-22 4:05 PM View: | Metzger Michael A Chief Executive Officer Director | Syndax Pharmaceuticals Inc (SNDX) | 06-Oct-22 | Planned Option Sale | 16,231 | $25.29 | $410,508.00 | (48%) 33.89K to 17.66K |
